Latest news

• bluebird bio aiming to separate business units by year-end

  ide-cel), which was approved by the US Food and Drug Administration (FDA) in March. ... According to bluebird bio, this decrease was driven primarily by a drop in license and manufacturing services revenue for ide-cel, as well as a decrease in revenue

• BMS and bluebird bio gain FDA approval for multiple myeloma therapy

  The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS) and bluebird bio’s BCMA-targeting CAR T cell therapy Abecma – previously known as ide-cel – for the ... In this heavily pre-treated group, ide-cel induced an overall

• bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin

  BMS) and monetisation for ex-US milestones and royalties from CAR T cell therapies ide-cel and bb21217. ... We remain focused on the upcoming prescription drug user fee act (PDUFA) action due date for ide-cel for multiple myeloma next month, the

• bluebird bio to separate oncology and rare diseases units

  Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being

• FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions

  BMS also agreed similar conditional payments, dependent on approval, for Celgene’s multiple sclerosis therapy Zeposia (ozanimod) and another CAR-T therapy, ide-cel (idecabtagene vicleucel). ... Zeposia was approved earlier this year, while ide-cel’s